Patents Assigned to PROXIMAGEN, LLC
-
Patent number: 11530208Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.Type: GrantFiled: September 17, 2015Date of Patent: December 20, 2022Assignee: PROXIMAGEN, LLCInventors: Lee Patient, Iain Simpson, Edward Savory
-
Patent number: 11512082Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.Type: GrantFiled: February 7, 2020Date of Patent: November 29, 2022Assignee: Proximagen, LLCInventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
-
Patent number: 11369616Abstract: The invention relates to a combination of CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1, 4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide and an immune checkpoint inhibitor, and the use of the same in the treatment of tumours and/or cancers.Type: GrantFiled: September 11, 2018Date of Patent: June 28, 2022Assignee: PROXIMAGEN, LLCInventor: Peter Richardson
-
Patent number: 11311552Abstract: The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers. The invention also relates to combination treatments with irradiation and/or a chemotherapeutic agent for use in the treatment of cancer.Type: GrantFiled: April 1, 2016Date of Patent: April 26, 2022Assignee: Proximagen, LLCInventors: Peter Richardson, Jacqueline Mary Walling, Claudio Festuccia
-
Patent number: 10995091Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.Type: GrantFiled: October 22, 2018Date of Patent: May 4, 2021Assignee: Proximagen LLCInventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
-
Patent number: 10968223Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)Type: GrantFiled: July 20, 2020Date of Patent: April 6, 2021Assignee: Proximagen, LLCInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Publication number: 20200347059Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)Type: ApplicationFiled: July 20, 2020Publication date: November 5, 2020Applicant: PROXIMAGEN, LLCInventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
-
Publication number: 20200281937Abstract: The invention relates to the use of the CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide or a pharmaceutically acceptable salt thereof in the treatment of cancers of the breast, bladder, colon, rectum and liver.Type: ApplicationFiled: March 9, 2018Publication date: September 10, 2020Applicant: Proximagen, LLCInventor: Peter RICHARDSON
-
Patent number: 10766897Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.Type: GrantFiled: August 16, 2019Date of Patent: September 8, 2020Assignee: PROXIMAGEN, LLCInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Publication number: 20200262835Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.Type: ApplicationFiled: February 7, 2020Publication date: August 20, 2020Applicant: PROXIMAGEN, LLCInventors: Max ESPENSEN, Lee PATIENT, David EVANS, Edward SAVORY, Iain SIMPSON
-
Patent number: 10738044Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl (4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.Type: GrantFiled: July 21, 2016Date of Patent: August 11, 2020Assignee: PROXIMAGEN, LLCInventor: Lee Patient
-
Publication number: 20200147059Abstract: Inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, are useful for the prevention and/or treatment of migraine, including headache, chronic migraine, episodic migraine, medication overuse headache disorder (MOU), migraine without aura, migraine with aura, migraine aura without headache, ocular migraine, vestibular migraine, basilar migraine, hemiplegic migraine, ophthalmoplegic migraine, and tension-type headache (TTH).Type: ApplicationFiled: June 8, 2018Publication date: May 14, 2020Applicant: Proximagen, LLCInventor: William PULLMAN
-
Patent number: 10590125Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.Type: GrantFiled: July 20, 2016Date of Patent: March 17, 2020Assignee: PROXIMAGEN, LLCInventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
-
Publication number: 20200002335Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.Type: ApplicationFiled: August 16, 2019Publication date: January 2, 2020Applicant: PROXIMAGEN, LLCInventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
-
Patent number: 10428066Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.Type: GrantFiled: March 5, 2018Date of Patent: October 1, 2019Assignee: PROXIMAGEN, LLCInventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
-
Publication number: 20190062333Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.Type: ApplicationFiled: October 22, 2018Publication date: February 28, 2019Applicant: Proximagen, LLCInventors: Edward Daniel SAVORY, Alison STEWART, Allison CARLEY, Giles BROWN, Iain SIMPSON, Kathryn OLIVER, Lee PATIENT, Michael HIGGINBOTTOM, Andrew Graham COLE
-
Patent number: 10155761Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.Type: GrantFiled: April 26, 2017Date of Patent: December 18, 2018Assignee: PROXIMAGEN, LLCInventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
